2 days ago
1
Orhan Turan/iStock via Getty Images
REGENXBIO (NASDAQ:RGNX) reported positive results from its trial investigating the gene therapy, clemidsogene lanparvovec (RGX-121), for Hunter syndrome treatment.
In the 12-month pivotal trial involving 13 participants, a significant finding was that after one year, there was an 82% median decrease in cerebrospinal
English (US) ·